Literature DB >> 19669326

Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.

Shilen Lakhani1, Lev Davidson, Dennis A Priebat, Averell H Sherker.   

Abstract

Imatinib (Gleevec, Novartis), an inhibitor of BCR-ABL, platelet-derived growth factor, and KIT receptor tyrosine kinases, is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. We describe a case of activation of chronic hepatitis B infection associated with imatinib therapy.

Entities:  

Year:  2008        PMID： 19669326      PMCID： PMC2716906          DOI： 10.1007/s12072-008-9099-5

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   6.047


  6 in total

1.  Histological features of acute hepatitis after imatinib mesylate treatment.

Authors:  C James; H Trouette; G Marit; P Cony-Makhoul; F-X Mahon
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

2.  Chronic hepatitis B: update of recommendations.

Authors:  Anna S F Lok; Brian J McMahon
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

3.  Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.

Authors:  K Ikeda; Y Shiga; A Takahashi; T Kai; H Kimura; K Takeyama; H Noji; K Ogawa; A Nakamura; H Ohira; Y Sato; Y Maruyama
Journal:  Leuk Lymphoma       Date:  2006-01

4.  Response of extraabdominal desmoid tumors to therapy with imatinib mesylate.

Authors:  Joseph Mace; J Sybil Biermann; Vernon Sondak; Cornelius McGinn; Curtis Hayes; Dafydd Thomas; Laurence Baker
Journal:  Cancer       Date:  2002-12-01       Impact factor: 6.860

5.  Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

Authors:  Silke Appel; Andreas M Boehmler; Frank Grünebach; Martin R Müller; Anette Rupf; Markus M Weck; Ulrike Hartmann; Volker L Reichardt; Lothar Kanz; Tim H Brümmendorf; Peter Brossart
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

Review 6.  Gastrointestinal stromal tumour.

Authors:  Brian P Rubin; Michael C Heinrich; Christopher L Corless
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321
  6 in total
  18 in total

Review 1.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

Review 2.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 3.  Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.

Authors:  Venessa Pattullo
Journal:  World J Hepatol       Date:  2015-05-08

Review 4.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 5.  Prevention and management of hepatitis B virus reactivation in cancer patients.

Authors:  Ka-Shing Cheung; Wai-Kay Seto; Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2016-01-06       Impact factor: 6.047

6.  Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages.

Authors:  Heiko Bruns; Frank Stegelmann; Mario Fabri; Konstanze Döhner; Ger van Zandbergen; Manfred Wagner; Mhairi Skinner; Robert L Modlin; Steffen Stenger
Journal:  J Immunol       Date:  2012-09-17       Impact factor: 5.422

Review 7.  Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.

Authors:  Bettina M Knoll; K Seiter
Journal:  Infection       Date:  2018-01-31       Impact factor: 3.553

8.  Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report.

Authors:  Yousef Mohammed Ali Hailan; Deena Mudawi; Mohamed A Yassin
Journal:  Case Rep Oncol       Date:  2021-06-24

Review 9.  Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors.

Authors:  Mark Reinwald; Tobias Boch; Wolf-Karsten Hofmann; Dieter Buchheidt
Journal:  Biomark Insights       Date:  2016-04-21

10.  Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.

Authors:  Guan-Min Lai; Sheng-Lei Yan; Cheng-Shyong Chang; Chien-Yu Tsai
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.